Adam C. Elnaggar

Oncology

7945 Wolf River Blvd
Germantown, TN 38138

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab.

Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab.

Journal: European urology oncology

Published: March 20, 2026

Erratum: Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors.

Erratum: Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors.

Journal: JCO precision oncology

Published: March 02, 2026

Testing for hereditary cancer genes in men: a missed opportunity for cancer prevention.

Testing for hereditary cancer genes in men: a missed opportunity for cancer prevention.

Journal: Frontiers in oncology

Published: December 12, 2025

ctDNA Dynamics and Recurrence Patterns after Organ-Sparing Trimodality Therapy for Bladder Cancer.

ctDNA Dynamics and Recurrence Patterns after Organ-Sparing Trimodality Therapy for Bladder Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 07, 2025

Using Circulating Tumor DNA-Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine Cancer.

Using Circulating Tumor DNA-Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine Cancer.

Journal: JCO precision oncology

Published: September 24, 2025

Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors.

Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors.

Journal: JCO precision oncology

Published: September 24, 2025

Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment?

Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment?

Journal: Gynecologic oncology

Published: August 25, 2025

Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities.

Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 11, 2025

Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma.

Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma.

Journal: JCO precision oncology

Published: December 18, 2024

Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis.

Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis.

Journal: Cancer

Published: August 08, 2024

Refining the interpretation of variants of uncertain significance in hereditary cancer screening through integrated RNA sequencing.

Refining the interpretation of variants of uncertain significance in hereditary cancer screening through integrated RNA sequencing.

Journal: Genetics in medicine open

Published: May 27, 2024

Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer.

Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer.

Journal: European urology oncology

Published: March 18, 2024

Showing 1-12 of 51

Last Updated: 09/26/2026